A Plus Biotechnology CoTPE:6918 -1.59%71 Operating Margin % is 23.44% as of Dec. 2025, which is 117% above its 10-year median of 10.82. GuruFocus rates TPE:6918 with a GF Score™ of 71/100 and a GF Value™ of NT$87.15 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 814 Medical Devices & Instruments companies, A Plus Biotechnology Co ranks better than 92.01% on this metric.
A Plus Biotechnology Co Ltd operating margin is expanding. Margin expansion is usually a good sign.
The historical rank and industry rank for A Plus Biotechnology Co's Operating Margin % or its related term are showing as below:
TPE:6918'
s Operating Margin % Range Over the Past 10 Years
Min: 6.92 Med: 10.82 Max: 24.98
Current: 24.98
TPE:6918's Operating Margin % is ranked better than 92.01% of 814
companies
in the Medical Devices & Instruments industry
Industry Median: 3.435
vs TPE:6918: 24.98
A Plus Biotechnology Co's 5-Year Average Operating Margin % Growth Rate was 34.30% per year.
A Plus Biotechnology Co (TPE:6918) Operating Margin % Explanation
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
A Plus Biotechnology Co Operating Margin % Related Terms
A Plus Biotechnology Co Operating Margin % Historical Data
* Premium members only.
The historical data trend for A Plus Biotechnology Co's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:6918 vs ABT, SYK, MDT: Operating Margin % Comparison
For the Medical Devices subindustry, A Plus Biotechnology Co's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
A Plus Biotechnology Co Operating Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, A Plus Biotechnology Co's Operating Margin % distribution charts can be found below:
* The bar in red indicates where A Plus Biotechnology Co's Operating Margin % falls into.
A Plus Biotechnology Co Operating Margin % Calculation
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
A Plus Biotechnology Co's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A Plus Biotechnology Co (TPE:6918) has a Operating Margin % of 23.44% as of Dec. 2025. Operating margin is the ratio of total operating income to net sales. View historical data on A Plus Biotechnology Co and its competitors. This is 117% above median its historical median of 10.82. Over the past decade, A Plus Biotechnology Co's Operating Margin % has ranged from 6.92 to 24.98. According to the industry distribution chart, A Plus Biotechnology Co ranks #65 out of 814 companies in the Medical Devices & Instruments industry, placing it in the top 8%.
Is A Plus Biotechnology Co's Operating Margin % too high?
A Plus Biotechnology Co's current Operating Margin % of 23.44% is 117% above median its 10-year median of 10.82. Over the past 10 years, this metric has ranged from a low of 6.92 to a high of 24.98. The Medical Devices & Instruments industry median Operating Margin % is 3.44. A Plus Biotechnology Co's value of 23.44% is 582.4% above this industry median. Based on the distribution chart, A Plus Biotechnology Co ranks #65 out of 814 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, A Plus Biotechnology Co has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does A Plus Biotechnology Co's Operating Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, A Plus Biotechnology Co ranks #65 out of 814 companies for Operating Margin %. This places A Plus Biotechnology Co in the top 8% of its industry — outperforming the majority of peers. The industry median Operating Margin % is 3.44. A Plus Biotechnology Co's value of 23.44% is 582.4% above this benchmark. Historically, A Plus Biotechnology Co's own Operating Margin % has ranged from 6.92 to 24.98 over the past decade. While the company's 10-year median is 10.82 vs. the industry median of 3.44, A Plus Biotechnology Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Medical Devices & Instruments company?
The median Operating Margin % among Medical Devices & Instruments companies is 3.44, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a Operating Margin % significantly above this median, while those in the bottom quartile fall well below. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. A Plus Biotechnology Co's current Operating Margin % of 23.44% is 582.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on A Plus Biotechnology Co and its competitors. For the Medical Devices & Instruments industry, the median Operating Margin % is 3.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. A Plus Biotechnology Co's current Operating Margin % is 23.44%, which is 117% above median its own 10-year median of 10.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is A Plus Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, A Plus Biotechnology Co (TPE:6918) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$87.15, compared to a current price of NT$74.30 — trading 14.7% below its estimated fair value. The current Operating Margin % is 23.44%, which is 117% above median its 10-year median of 10.82 and 582.4% above the Medical Devices & Instruments industry median of 3.44. A Plus Biotechnology Co's overall GF Score™ is 71/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For A Plus Biotechnology Co (TPE:6918), the current Operating Margin % is 23.44% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is A Plus Biotechnology Co (TPE:6918) Overvalued in 2026?
Based on GuruFocus' analysis, A Plus Biotechnology Co stock appears to be undervalued.
The current stock price of NT$74.30 is trading 14.7% below its estimated GF Value™ of NT$87.15.
GuruFocus considers A Plus Biotechnology Co to be Modestly Undervalued.
Key valuation signals for TPE:6918:
Operating Margin %: 23.44% (117% above median its 10-year median of 10.82)
GF Value™: NT$87.15 vs. price of NT$74.30 (14.7% below fair value)
Industry Position: 582.4% above the Medical Devices & Instruments median (#65 of 814)
No single metric tells the full story. See the TPE:6918 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
A Plus Biotechnology Co Ltd provides orthopedic implants and engages in the manufacturing and wholesale of medical devices such as bone material. The company's products include Chest, Shoulder, Spine, Elbow, Wrist & Hand, Pelvic & Hip, Knee, Foot & Ankle, Osteotomy, Pediatric & ESF, and Biologics. The company currently has operating segments in Taiwan and China, with the majority of revenue coming from Taiwan.
71GF Score
Get the complete analysis for TPE:6918
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6918 has been successfully added to your 
